natgillin/translations-raw huggingface dataset:
Temozolomide is first used together with radiotherapy (concomitant phase of treatment) and after that alone (monotherapy phase of treatment). children 3 years and older and adult patients with specific forms of brain tumour (e.g. glioblastoma multiforme or anaplastic. astrocytoma) that has returned or where the cancer has spread after standard therapy.
Temozolomid se prvo primjenjuje u kombinaciji s radioterapijom (faza istodobnog liječenja), a zatim samostalno (faza monoterapije). djece u dobi od 3 godine i starije te u odraslih bolesnika sa specifičnim oblikom tumora mozga (npr. multiformni glioblastom ili anaplastični astrocitom) kada se tumor ponovno pojavio ili se širi nakon standardne terapije.
Temozolomide Sandoz 100 mg capsules Temozolomide
Temozolomid Sandoz 100 mg kapsule temozolomid
Temozolomide Sandoz 100 mg capsules Temozolomide
Temozolomid Sandoz 100 mg tvrde kapsule temozolomid
Temozolomide Sandoz 100 mg hard capsules Temozolomide
Temozolomid Sandoz 100 mg tvrde kapsule Temozolomid
Temozolomide Sandoz 140 mg capsules Temozolomide
Temozolomid Sandoz 140 mg kapsule temozolomid
Temozolomide Sandoz 140 mg capsules Temozolomide
Temozolomid Sandoz 140 mg tvrde kapsule temozolomid
Temozolomide Sandoz 140 mg hard capsules Temozolomide
Temozolomid Sandoz 140 mg tvrde kapsule temozolomid
Temozolomide Sandoz 180 mg capsules Temozolomide
Temozolomid Sandoz 180 mg kapsule temozolomid
Temozolomide Sandoz 180 mg capsules Temozolomide
Temozolomid Sandoz 180 mg tvrde kapsule temozolomid
Temozolomide Sandoz 180 mg hard capsules Temozolomide
Temozolomid Sandoz 180 mg tvrde kapsule Temozolomid
Temozolomide Sandoz 20 mg capsules Temozolomide
Temozolomid Sandoz 20 mg kapsule temozolomid
Temozolomide Sandoz 20 mg capsules Temozolomide
Temozolomid Sandoz 20 mg tvrde kapsule temozolomid
Temozolomide Sandoz 20 mg hard capsules Temozolomide
Temozolomid Sandoz 20 mg tvrde kapsule temozolomid
Temozolomide Sandoz 250 mg capsules Temozolomide
Temozolomid Sandoz 250 mg kapsule temozolomid
Temozolomide Sandoz 250 mg capsules Temozolomide
Temozolomid Sandoz 250 mg tvrde kapsule temozolomid
Temozolomide Sandoz 250 mg hard capsules Temozolomide
Temozolomid Sandoz 250 mg tvrde kapsule Temozolomid
Temozolomide Sandoz 5 mg capsules Temozolomide
Temozolomid Sandoz 5 mg kapsule temozolomid
Temozolomide Sandoz 5 mg capsules Temozolomide
Temozolomid Sandoz 5 mg tvrde kapsule temozolomid
Temozolomide Sandoz 5 mg hard capsules Temozolomide
Temozolomid Sandoz 5 mg tvrde kapsule temozolomid
Temozolomide Sandoz is a ‘generic medicine’.
Temozolomide Sandoz je „generički lijek”.
Temozolomide Sandoz is administered in combination with focal radiotherapy (concomitant phase) followed by up to 6 cycles of temozolomide (TMZ) monotherapy (monotherapy phase).
Temozolomid Sandoz se primjenjuje u kombinaciji s fokalnom radioterapijom (faza istodobnog liječenja), nakon čega slijedi do 6 ciklusa monoterapije temozolomidom (TMZ) (faza monoterapije).
Temozolomide Sandoz is an anticancer medicine.
Temozolomide Sandoz je citostatik.
Temozolomide Sandoz is first used together with radiotherapy (concomitant phase of treatment) and after that alone (monotherapy phase of treatment). in children 3 years and older and adult patients with malignant glioma , such as glioblastoma multiforme or anaplastic astrocytoma.
Temozolomid Sandoz se najprije koristi zajedno sa zračenjem (faza istodobnog liječenja), a zatim kao jedini lijek (faza monoterapije). u djece u dobi od 3 godine i starije te u odraslih bolesnika s malignim gliomom, kao što je multiformni glioblastom ili anaplastični astrocitom.
Temozolomide Sandoz is indicated for the treatment of: adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment, children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Temozolomid Sandoz indiciran je za liječenje: odraslih bolesnika s novodijagnosticiranim multiformnim glioblastomom, istodobno s radioterapijom (RT), a zatim kao monoterapija, djece od navršene tri godine starosti, adolescenata i odraslih bolesnika s malignim gliomom, kao što je multiformni glioblastom ili anaplastični astrocitom, koji je recidivirao ili napreduje nakon standardne terapije.
Temozolomide Sandoz is used first with radiotherapy and then on its own; adults and children three years of age and over with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, when the tumour has returned or got worse after standard treatment.
Temozolomide Sandoz se prvo koristi istodobno s radioterapijom (RT), a zatim kao monoterapija; odraslih bolesnika i djece od navršene tri godine starosti s malignim gliomom, kao što je multiformni glioblastom ili anaplastični astrocitom, koji je recidivirao ili napreduje nakon standardne terapije.
Temozolomide Sandoz is used for the treatment of specific forms of brain tumours: in adults with newly-diagnosed glioblastoma multiforme.
Temozolomid Sandoz se koristi za liječenje određenih vrsta tumora mozga: u odraslih s novodijagnosticiranim multiformnim glioblastomom.
Temozolomide Sandoz should only be prescribed by physicians experienced in the oncological treatment of brain tumours.
Temozolomid Sandoz smiju propisivati samo liječnici s iskustvom u onkološkom liječenju tumora mozga.
Temozolomide Sandozl 20 mg hard capsules Temozolomide
Temozolomid Sandoz 20 mg tvrde kapsule Temozolomid
Temozolomide SUN 140 mg hard capsules Temozolomide
Temozolomid SUN 140 mg tvrde kapsule temozolomid
Temozolomide SUN 20 mg hard capsules
Temozolomid SUN20 mg tvrde kapsule
Temozolomide SUN 20 mg hard capsules Temozolomide
Temozolomid SUN 20 mg tvrde kapsule temozolomid
Temozolomide SUN 250 mg hard capsules Temozolomide
Temozolomid SUN 250 mg tvrde kapsule temozolomid
Temozolomide SUN 5 mg hard capsules Temozolomide
Temozolomid SUN 5 mg tvrde kapsule temozolomid
Temozolomide SUN is at first used
Temozolomid SUN
Temozolomide SUN is indicated for the treatment of: adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment. children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Temozolomid SUN je indiciran za liječenje: odraslih bolesnika s novodijagnosticiranim multiformnim glioblastomom, istodobno s radioterapijom (RT), a zatim kao monoterapija. djece od navršene tri godine starosti, adolescenata i odraslih bolesnika s malignim gliomom, kao što je multiformni glioblastom ili anaplastični astrocitom, koji je recidivirao ili napreduje nakon standardne terapije.
Temozolomide SUN is used for the treatment of specific forms of brain tumours: in adults with newly-diagnosed glioblastoma multiforme.
Temozolomid SUN se koristi za liječenje određenih vrsta tumora mozga: u odraslih bolesnika s novodijagnosticiranim multiformnim glioblastomom.
Temozolomide SUN may make you feel tired or sleepy.
Temozolomid SUN može uzrokovati umor ili pospanost.
Temozolomide SUN should be administered in the fasting state.
Temozolomid SUN tvrde kapsule moraju se uzimati natašte.
Temozolomide SUN should only be prescribed by physicians experienced in the oncological treatment of brain tumours.
Temozolomid SUN smiju propisivati samo liječnici s iskustvom u onkološkom liječenju tumora mozga.
Temozolomide Teva 100 mg hard capsules: (including printing ink): gelatin, titanium dioxide (E171), red iron oxide (E172), shellac, propylene glycol and yellow iron oxide (E172).
Temozolomid Teva 100 mg tvrde kapsule: (uključujući tintu za označavanje): želatina, titanijev dioksid (E171), crveni željezov oksid (E172) šelak, propilenglikol i žuti željezov oksid (E172).
Temozolomide Teva 140 mg hard capsules: (including printing ink): gelatin, titanium dioxide (E171), shellac, propylene glycol, Indigo carmine (E132) aluminium lake
Temozolomid Teva 140 mg tvrde kapsule: (uključujući tintu za označavanje): želatina, titanijev dioksid (E171), šelak, propilenglikol, indigo carmine (E132) aluminium lake.
Temozolomide Teva 180 mg hard capsules: (including printing ink): gelatin, titanium dioxide (E171), shellac, propylene glycol, red iron oxide (E172)
Temozolomid Teva 180 mg tvrde kapsule: (uključujući tintu za označavanje): želatina, titanijev dioksid (E171), šelak, propilenglikol, crveni željezov oksid (E172).
Temozolomide Teva 20 mg hard capsules: (including printing ink): gelatine, titanium dioxide (E171), shellac, propylene glycol, Sunset yellow FCF Aluminium Lake (E110)
Temozolomid Teva 20 mg tvrde kapsule: (uključujući tintu za označavanje): želatina, titanijev dioksid (E171), šelak, propilenglikol, sunset yellow FCF aluminium lake (E110)
Temozolomide Teva 5 mg hard capsules: (including printing ink): gelatin, titanium dioxide (E171), shellac, propylene glycol, Indigo carmine (E132) aluminium lake, yellow iron oxide (E172)
Temozolomid Teva 5 mg tvrde kapsule: (uključujući tintu za označavanje): želatina, titanijev dioksid (E171), šelak, propilenglikol, indigo carmine (E132) aluminium lake, žuti željezov oksid (E172).
Temozolomide Teva contain lactose (a kind of sugar).
Temozolomid Teva tvrde kapsule sadrže laktozu (vrstu šećera).
Temozolomide Teva is a cancer medicine.
Temozolomide Teva je citostatik.
Temozolomide Teva is a ‘generic medicine’.
Temozolomide Teva je „generički lijek”.
Temozolomide Teva is first used together
Temozolomid Teva
Temozolomide Teva is indicated for the treatment of: adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment. children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Temozolomid Teva je indiciran za liječenje: odraslih bolesnika s novodijagnosticiranim multiformnim glioblastomom, istodobno s radioterapijom (RT), a zatim kao monoterapija. djece od navršene tri godine starosti, adolescenata i odraslih bolesnika s malignim gliomom, kao što je multiformni glioblastom ili anaplastični astrocitom, koji je recidivirao ili napreduje nakon standardne terapije.
Temozolomide Teva is used first with radiotherapy and then on its own; adults and children three years of age and over with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, when the tumour has returned or got worse after standard treatment.
Temozolomide Teva se prvo koristi istodobno s radioterapijom (RT), a zatim kao monoterapija; odraslih bolesnika i djece od navršene treće godine starosti s malignim gliomom, kao što je multiformni glioblastom ili anaplastični astrocitom, koji je recidivirao ili napreduje nakon standardne terapije.
Temozolomide Teva is used for the treatment of specific forms of brain tumours: in adults with newly-diagnosed glioblastoma multiforme.
Temozolomid Teva se koristi za liječenje određenih vrsta tumora mozga: u odraslih bolesnika s novodijagnosticiranim multiformnim glioblastomom.
Temozolomide Teva monotherapy in recurrent or progressive glioma
Monoterapija lijekom Temozolomid Teva u bolesnika s ponovnom pojavom ili pogoršanjem glioma
Temozolomide Teva should only be prescribed by physicians experienced in the oncological treatment of brain tumours.
Temozolomid Teva smiju propisivati samo liječnici s iskustvom u onkološkom liječenju tumora mozga.
Temperature of ≥ 40°C within 48 hours not due to another identifiable cause;
Temperatura ≥ 40°C unutar 48 sati ako se ne može ustanoviti drugi uzrok;
Temperature of  40.0°C within 48 hours, not due to another identifiable cause;
Temperatura  40,0°C unutar 48 sati, koja se ne može dovesti u vezu s bilo kojim drugim uzrokom;
temporal arteritisd
temporalni arteritisd
Temporal association of olanzapine treatment and venous thromboembolism been reported uncommonly (≥ 0.1% and < 1%).
Vremenska povezanost liječenja olanzapinom i venske tromboembolije (VTE) zabilježena je manje često (< 0,01 % i < 1 %).
Temporal association of olanzapine treatment and venous thromboembolism been reported uncommonly (≥ 0.1% and < 1%).
Vremenska povezanost liječenja olanzapinom i venske tromboembolije (VTE) zabilježena je manje često (< 0,01% i < 1%).
Temporal association of olanzapine treatment and venous thromboembolism has been reported uncommonly (≥ 0.1% and < 1%).
Vremenska povezanost liječenja olanzapinom i venske tromboembolije (VTE) zabilježena je manje često (< 0,01% i < 1%).
Temporal association of olanzapine treatment and venous thromboembolism has been reported uncommonly (≥ 0.1% and < 1%)..
Vremenska povezanost liječenja olanzapinom i venske tromboembolije (VTE) zabilježena je manje često (< 0,01% i < 1%).
Temporarily discontinue Fexeric if the serum phosphorus is < 3 mg/dl and resume at a lower dose once the serum phosphorus has returned to the target range.
Ako je razina fosfora u serumu < 3 mg/dl potrebno je privremeno prekinuti primjenu Fexerica i nastaviti s primjenom manje doze nakon što se vrijednost fosfora u serumu vrati unutar ciljnog raspona.
temporarily stopping breathing (apnoea)
privremeni prekid disanja (apneja)
Temporarily stopping the infusion usually resolves these symptoms without further therapy.
Privremenim prekidom infuzije ovi simptomi obično nestanu bez dodatne terapije.
Temporarily suspend Caelyx treatment in patients when the ANC count is < 1,000/mm3 and/or the platelet count is < 50,000/mm3.
Privremeno prekinite liječenje bolesnika Caelyxom kad im je ANC < 1.000/mm3 i/ili broj trombocita < 50.000/mm3.
Temporarily withhold, for a maximum of 6 weeks following Day 1 of the most recent treatment cycle, until symptoms resolve to Grade ≤ 2.
Privremeno odgoditi primjenu – za najviše 6 tjedana počevši od dana posljednjeg ciklusa liječenja – dok se simptomi ne ublaže do ≤ 2. stupnja.
Temporary changes to vision with long term use.
Prolazne promjene vida tijekom dugotrajne primjene.
Temporary discontinuation
Privremen prekid liječenja
Temporary dose interruption until recovery to Grade 1 (≥75x109/l).
Privremeni prekid primjene do oporavka do stupnja 1 (≥75x109/l).
Temporary dose interruption until recovery to Grade 1.
Privremeni prekid primjene do oporavka do stupnja 1.
Temporary dose interruption until recovery to Grade 1.
Privremeno prekinuti primjenu do oporavka na stupanj 1.
Temporary dose interruption until recovery to Grade 2 (≥1.25x109/l) and no fever.
Privremeni prekid primjene do oporavka do stupnja 2 (≥1,25x109/l) i povlačenja vrućice.
Temporary dose interruption until recovery to Grade 2 (≥1.25x109/l) and no fever.
Privremeni prekid primjenu do oporavka do stupnja 2 (≥1,25x109/l) i povlačenja vrućice.
Temporary dose interruption until recovery to Grade 2 (≥1x109/l).
Privremeni prekid primjene do oporavka do stupnja 2 (≥1x109/l).
Temporary dose interruption.
Privremeni prekid primjene.
Temporary dose reduction to 120 mg twice a day may reduce the occurrence of flushing and gastrointestinal adverse reactions.
Privremeno smanjenje doze na 120 mg dva puta na dan može smanjiti pojavu crvenila uz osjećaj vrućine i nuspojave probavnog sustava.
temporary increased cholesterol or triglyceride (fats) levels in the blood
prolazan porast razina kolesterola i triglicerida (masnoća) u krvi
Temporary increases in transaminases to twice or three times of the upper limit of normal have been reported in patients at a frequency of 13-20 %.
Prolazno povišenje transaminaza na vrijednosti koje su dvostruko ili trostruko više od gornje granice normale zabilježeno je u bolesnika s učestalošću od 13-20%.
Temporary interruption of zoledronic acid treatment should be considered until the condition resolves and contributing risk factors are mitigated where possible.
Kad je moguće treba uzeti u obzir privremeni prekid liječenja zoledronatnom kiselinom dok se stanje ne popravi i pripadajući čimbenici rizika ublaže
temporary loss of finger or toe nails of the affected arm or leg
privremeni gubitak noktiju na prstima ruku ili nogu bolesne ruke ili noge
Temporary loss of vision
privremeni gubitak vida
Temporary or permanent immobilisation due to e.g. post-surgical recovery or prolonged bed rest.
Privremenom ili trajnom imobilizacijom zbog npr. opravka poslije operacije ili produljenog mirovanja u krevetu.
Temporary reduction in the number of blood particles called platelets which can result in bruising or bleeding, temporary swelling of the glands in the neck, armpit or groin.
Privremeno smanjenje broja određenih krvnih stanica zvanih krvne pločice, što može rezultirati stvaranjem modrica ili krvarenjem
Temporary signs may be noticed at the site of application of the product, such as a wetness and a white colour, but these signs do not affect the safety or effectiveness of the product.
Privremeni se znakovi mogu uočiti u mjestu primjene proizvoda, poput primjerice da je područje mokro i bijele boje, no ovi znakovi ne utječu na sigurnost ili djelotvornost proizvoda.
Temporary suspension of sunitinib is recommended; following resolution, treatment may be resumed at the discretion of the treating physician.
Preporučuje se privremen prekid primjene sunitiniba; nakon što se stanje popravi, prema odluci nadležnog liječnika liječenje se može nastaviti.
Temporary suspension or sudden cessation of breathing
privremeni prekid ili nagli prestanak disanja
Temporo-parietal aspects including Insula (in, axial review and tp-in, coronal review)
Temporo-parijetalne dijelove uključujući inzulu (in, aksijalni prikaz i tp-in, koronarni prikaz)
Temsirolimus also was associated with statistically significant advantages over IFN-α in the secondary endpoints of PFS, TTF, and clinical benefit rate.
Temsirolimus je također bio povezan sa statistički značajnim prednostima nad IFN-α u drugim ishodima: preživljenju bez progresije bolesti, vremenu do neuspjeha liječenja i stopi kliničke koristi.
Temsirolimus also was associated with statistically significant advantages over investigator’s choice in the secondary endpoint of ORR.
Temsirolimus je također bio povezan sa statistički značajnim prednostima nad terapijom po izboru ispitivača u sekundarnoj mjeri ishoda ORR.
Temsirolimus and sirolimus were demonstrated to be substrates for P-gp in vitro.
Pokazalo se da su temsirolimus i sirolimus supstrati P-gp in vitro.
Temsirolimus Concentrate for Injection 175/75 mg n = 54
Temsirolimus koncentrat za injekciju 175/75 mg n = 54
Temsirolimus distribution is dose-dependent with mean (10th, 90th percentiles) maximal specific binding in blood cells of 1.4 mg (0.47 to 2.5 mg).
Distribucija temsirolimusa je ovisna o dozi uz srednju vrijednost (10.-90.percentila) maksimalno specifičnog vezanja u krvnim stanicama od 1,4 mg (0,47 do 2,5 mg).
Temsirolimus dose modifications based on weekly ANC and platelet counts
Prilagodbe doze temsirolimusa na temelju tjednog apsolutnog broja neutrofila i broja trombocita
Temsirolimus is a selective inhibitor of mTOR (mammalian target of rapamycin) that blocks tumour cell growth and division.
Temsirolimus je selektivni inhibitor mTOR (ciljne molekule u sisavaca za rapamicin) koji blokira rast i dijeljenje tumorskih stanica.
Temsirolimus is cleared predominantly by the liver.
Temsirolimus najvećim dijelom uklanja jetra.
Temsirolimus should be used with caution in patients with hepatic impairment (see section 4.4).
Temsirolimus se mora primjenjivati s oprezom u bolesnika s oštećenjem funkcije jetre (vidjeti dio 4.4).
Temsirolimus should be used with caution when treating patients with hepatic impairment.
Temsirolimus treba primjenjivati s oprezom kad se liječe bolesnici s oštećenjem jetre.
TEMSO-study
Ispitivanje TEMSO
Ten days after the booster dose, the seroprotection rate against A/Turkey/Turkey/1/2005 and A/Indonesia/5/2005 was 99.2%.
Deset dana od primitka doze za docjepljivanje, stopa seroprotekcije protiv A/Turkey/Turkey/1/2005 i A/Indonesia/5/2005 bila je 99,2%.
Ten patients with advanced late-onset Pompe disease (i.e. wheelchair-bound for 10/10 and ventilator- dependent for 9/10) aged 9-54 years were treated in expanded access programs with alglucosidase alfa 20-40 mg/kg once every two weeks for various periods of time between 6 months and 2.5 years.
Deset bolesnika s uznapredovalim kasnim oblikom Pompeove bolesti (10/10 vezanih za invalidska kolica i 9/10 ovisnih o respiratoru) u dobi od 9 do 54 godine liječeno je u programu proširenog pristupa alglukozidazom alfa u dozi od 20–40 mg/kg jedanput svaka dva tjedna tijekom različitih vremenskih razdoblja između 6 mjeseci i 2,5 godine.
Ten percent of patients have a mean terminal elimination half- life greater than 100 hours.
Deset posto bolesnika ima terminalni poluvijek eliminacije dulji od 100 sati.
Ten percent of subjects (17/168) were cirrhotic, including 3 (6%) prior null responders, 2 (7%) prior relapsers, and 12 (14%) prior partial responders.
Deset posto ispitanika (17/168) je imalo cirozu, uključujući 3 (6%) ispitanika koja nisu odgovorila na prethodno liječenje, 2 (7%) ispitanika koja su doživjela relaps kod prethodnog liječenja i 12 (14%) ispitanika koji su ostvarili djelomičan odgovor na prethodno liječenje.
Ten placebo controlled trials have been performed to investigate the short term efficacy of Thymanax in major depressive disorder in adults, with fixed dose and/or dose up-titration.
Izvršeno je deset placebom kontroliraninih kliničkih ispitivanja kako bi se ispitala kratkoročna djelotvornost lijeka Thymanax kod velikog depresivnog poremećaja u odraslih, s fiksnom dozom i/ili sa titracijom doza.
Ten placebo controlled trials have been performed to investigate the short term efficacy of Valdoxan in major depressive disorder in adults, with fixed dose and/or dose up-titration.
Izvršeno je deset placebom kontroliraninih kliničkih ispitivanja kako bi se ispitala kratkoročna djelotvornost lijeka Valdoxan kod velikog depresivnog poremećaja u odraslih, s fiksnom dozom i/ili sa titracijom doza.
Ten subjects were weaned off their parenteral support while on Revestive treatment for 30 months.
Parenteralna potpora ukinuta je kod desetero ispitanika tijekom liječenja Revestivom u trajanju od 30 mjeseci.
Ten times the maximum dose was shown to be safe for the target species by all the recommended routes and methods of administration.
Deseterostruka maksimalna doza, kod svih preporučenih načina i metoda primjene, je neškodljiva za životinje kojima je proizvod namijenjen.
tenderness
osjetljivost
Tenderness
osjetljivosti na dodir
Tenderness (pain) around the stomach (abdomen)
vrbež osjetljivost (bol) u području želuca (trbuha)
tenderness in ligament at base of penis
osjetljivost ligamenta kod korijena penisa
Tenderness in the abdomen
osjetljivost u trbuhu
tenderness or discomfort at the injection site (including severe injection site tenderness resulting in crying when injected limb is moved)
osjetljivost ili nelagoda na mjestu injiciranja (uključujući jaku osjetljivost na mjestu injiciranja koja rezultira plakanjem uslijed pomicanja injicirane ruke ili noge)
tenderness, and swelling over the implant site, heterotopic ossification / myositis ossificans (bone formation outside of the fracture area).
osjetljivost i oticanje iznad mjesta implantacije, heterotopična osifikacija / osificirajući miozitis (formiranje koštanog tkiva izvan područja loma).
Tenderness, erythema, irritability, unusual crying, sleepiness, diarrhoea and change in eating habits.
osjetljivost, eritem, razdražljivost, neuobičajeno plakanje, pospanost, proljev i promjene u prehrambenim navikama.
Tenderness, erythema, irritability, unusual crying, sleepiness, diarrhoea, vomiting and change in eating habits.
Pojačana osjetljivost, eritem, razdražljivost, neuobičajena plačljivost, pospanost, proljev, povraćanje i promjena apetita.
tenderness, groin
osjetljivost na
Tendinitis and tendon rupture, sometimes bilateral, may occur within 48 hours of starting treatment with levofloxacin and have been reported up to several months after discontinuation of treatment.
Tendinitis i ruptura tetive, ponekad bilateralna, može se javiti unutar 48 sati od početka liječenja levofloksacinom, a prijavljeni su slučajevi i do nekoliko tjedana nakon prestanka liječenja.